Fractyl Health, Inc. reports clinical and corporate developments as a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes. Its lead product candidate, Revita®, is a minimally invasive endoscopic therapy designed to remodel the duodenal lining for post-GLP-1 weight maintenance; it is investigational in the United States, has FDA Breakthrough Device designation, and is CE marked in the European Union and United Kingdom.
Company news also covers the Rejuva® AAV-based gene therapy platform, including RJVA-001 for type 2 diabetes and RJVA-002 for obesity, as well as clinical data from REMAIN-1, regulatory authorizations, financial results, capital-plan updates and public-company governance changes.
Fractyl Health, Inc. (Nasdaq: GUTS) will present at BofA Securities 2024 Health Care Conference. Dr. Harith Rajagopalan, CEO, will participate in a fireside chat on May 15, 2024. The Company focuses on innovative treatments for obesity and type 2 diabetes.
Fractyl Health, Inc. (Nasdaq: GUTS) will report Q1 2024 financial results and business updates on May 13, 2024. The company focuses on metabolic therapeutics for obesity and T2D, hosting a conference call at 4:30 p.m. ET.
Fractyl Health, Inc. (Nasdaq: GUTS) will present new data at the German Diabetes Association (DDG) Annual Meeting on its real-world registry study of Revita for T2D and at the Digestive Disease Week (DDW) on the potential of Rejuva in reducing liver fat. The presentations include clinical updates and preclinical data demonstrating the effectiveness of their metabolic therapeutics in treating obesity and T2D.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.